TW202304964A - Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途 - Google Patents

Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途 Download PDF

Info

Publication number
TW202304964A
TW202304964A TW111114234A TW111114234A TW202304964A TW 202304964 A TW202304964 A TW 202304964A TW 111114234 A TW111114234 A TW 111114234A TW 111114234 A TW111114234 A TW 111114234A TW 202304964 A TW202304964 A TW 202304964A
Authority
TW
Taiwan
Prior art keywords
hla
peptide
magec2
cells
tcr
Prior art date
Application number
TW111114234A
Other languages
English (en)
Chinese (zh)
Inventor
安德魯 Ｐ 費雷堤
王伊帆
蓋賓 麥克比思
許其開
Original Assignee
美商帝斯肯醫療公司
荷蘭萊登大學醫學中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商帝斯肯醫療公司, 荷蘭萊登大學醫學中心 filed Critical 美商帝斯肯醫療公司
Publication of TW202304964A publication Critical patent/TW202304964A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
TW111114234A 2021-04-14 2022-04-14 Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途 TW202304964A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163174808P 2021-04-14 2021-04-14
US63/174,808 2021-04-14
US202263329523P 2022-04-11 2022-04-11
US63/329,523 2022-04-11

Publications (1)

Publication Number Publication Date
TW202304964A true TW202304964A (zh) 2023-02-01

Family

ID=83641016

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111114234A TW202304964A (zh) 2021-04-14 2022-04-14 Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途

Country Status (11)

Country Link
US (1) US20240190931A1 (https=)
EP (1) EP4323379A4 (https=)
JP (1) JP2024515646A (https=)
KR (1) KR20240007162A (https=)
AU (1) AU2022256469A1 (https=)
BR (1) BR112023021162A2 (https=)
CA (1) CA3216553A1 (https=)
IL (1) IL307601A (https=)
MX (1) MX2023012141A (https=)
TW (1) TW202304964A (https=)
WO (1) WO2022221479A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820429A (zh) * 2024-01-11 2024-04-05 中国水产科学研究院南海水产研究所 一种具有inos抑制作用的乌鳢源活性肽

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025202443A1 (en) * 2024-04-08 2025-10-23 Tscan Therapeutics, Inc. Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
CN120098931A (zh) * 2025-02-10 2025-06-06 武建强 具有杀伤和肿瘤抑制功效的tcr-t细胞及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US9205144B2 (en) * 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
GB201520539D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN119930795A (zh) * 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
US20210061914A1 (en) * 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
CN112004825A (zh) * 2018-02-12 2020-11-27 弗雷德哈钦森癌症研究中心 细胞周期蛋白a1特异性t细胞受体及其用途
CN112368386A (zh) * 2018-05-23 2021-02-12 磨石肿瘤生物技术公司 共有抗原
CN112888707B (zh) * 2018-08-16 2025-04-25 百欧恩泰美国公司 T细胞受体构建体及其用途
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
SG11202103609YA (en) * 2018-10-25 2021-05-28 Council Queensland Inst Medical Res T-cell receptors and uses thereof
EP3917542A4 (en) * 2019-01-29 2023-03-08 Gritstone bio, Inc. MULTISPECIFIC BINDING PROTEINS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820429A (zh) * 2024-01-11 2024-04-05 中国水产科学研究院南海水产研究所 一种具有inos抑制作用的乌鳢源活性肽

Also Published As

Publication number Publication date
KR20240007162A (ko) 2024-01-16
WO2022221479A3 (en) 2022-11-24
EP4323379A4 (en) 2025-12-17
IL307601A (en) 2023-12-01
AU2022256469A1 (en) 2023-10-12
BR112023021162A2 (pt) 2024-01-16
EP4323379A2 (en) 2024-02-21
US20240190931A1 (en) 2024-06-13
WO2022221479A2 (en) 2022-10-20
CA3216553A1 (en) 2022-10-20
JP2024515646A (ja) 2024-04-10
MX2023012141A (es) 2023-11-28

Similar Documents

Publication Publication Date Title
US20230270832A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
US20230272049A1 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof
US20240190931A1 (en) Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
IL302616A (en) Binding of proteins that recognize Ha-1 antigen and their use
US20250249039A1 (en) Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
AU2024227623B2 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
AU2023241307B2 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
WO2025217028A1 (en) Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
CN118613497A (zh) Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
CN118382631A (zh) Magec2免疫原性肽、识别magec2免疫原性肽的结合蛋白及其用途
JPWO2023086477A5 (https=)
CN118510797A (zh) 识别hpv16 e7抗原的结合蛋白和其用途